Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...

The announcement comes after a request was made by the Canadian Investment Regulatory Organization (CIRO) to explore the ...

Ophthalmology Times spoke with Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis about how her ...

The pandemic caused an overall decrease in the rates of the 10 most common ophthalmic procedures performed in 2020 when ...

Shan Lin, MD, speaks to the new MIGS entering the glaucoma space and providing additional options for patients and providers ...

Inder Paul Singh, MD, speaks to the potential of artificial intelligence (AI) in the management of the glaucoma disease state ...

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

Sonia H. Yoo, MD, a cornea, cataract, and refractive surgery specialist and a member of the planning committee for the ...

Sunita Radhakrishnan, MD, shares insights on the use of electric neurostimulation and its potential use in the treatment of glaucoma, as evidenced by its current use in Europe and the upcoming trials ...

Andrew Iwach, MD, shares how Glaucoma 360 got its start and how today's meeting focuses on innovation that can benefit ...

Patients commonly reported unexplained blurred or hazy vision postoperatively that requires further investigation ...